Variety of eligible individuals: CDEC mentioned the uncertainty in the number of patients with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or average disorder could possibly have a significant https://hemgenix16058.diowebhost.com/90736879/everything-about-hemgenix